Pharmaceuticals, Biotechnology and Life Sciences
Innate Pharma will speed up the development of its anti-KIR3DL2 antibody, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.
Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
Innate Pharma has announced key leadership team and Board changes which will take effect on December 30th, 2016.
Bristol-Myers Squibb Company and Innate Pharma SA today announced safety data for two Phase I studies conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors.